6th Annual Risk Management and Pharmacovigilance Summit

Pharmacovigilance is an essential element for effective use of medicines and for public health. The aim is to minimise the risk of any harm that may come to patients and it is necessary for all PV professionals to keep pace with the new trends, regulations and requirements.

The 6th Annual Risk Management and Pharmacovigilance Summit will be held in Vienna this September and like every year, it will create a great atmosphere for PV professionals to network and discuss current issues in the drug safety world. You will hear about all the necessary topics related to the new updates in regulatory, the use of Real World Data, new techniques in digital pharmacovigilance, real examples of benefit-risk evaluation and signal detection, how to go through the inspection, clinical drug safety, patient involvement and many more. Do not forget to highlight the dates 17 - 19 September in your calendar and prepare yourself for 3 days full of great presentations, discussions and networking. We are looking forward to meeting you in the best Pharmacovigilance and Risk Management Summit soon!

Join us and register today

Stay on top of the latest trends

Key speakers

Andreas Osanger

Andreas Osanger

Head of Clinical Drug Safety
Susan Bhatti

Susan Bhatti

Director EU Global Regulatory and Scientific Policy
Richard HUGHES

Richard HUGHES

Safety Science Senior Medical Director
Sally Lee

Sally Lee

Senior Director, Epidemiology, Global Drug Safety and Risk Management
Nicola Groth

Nicola Groth

Head Safety Evaluation & Risk Management Italy
Bolatito Abatan

Bolatito Abatan

Associate Director, Growth & Emerging Markets, PV Affiliate Relations

Key topics

  • Use of Real World Data in Supporting Pharmacovigilance
  • Pharmacovigilance in the Emerging Markets
  • Strategic Partnerships in PV
  • Strategic Drug Safety & PhV: Learnings and Practical Considerations
  • QPPV Regulations in Non-EU Countries - Implications for Multi-/National MAH
  • From Clinical Monitoring to Signal Detection in Clinical Development
  • The Role of Quality Assurance in PV
  • Patient Involvement in Clinical Development of Medicines
  • Integrating Safety Evidence

Who Should Attend

Who Should Attend - Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from pharmaceutical industry involved in:

  • Pharmacovigilance
  • Drug Safety
  • Safety & Risk Management
  • Signal Detection
  • Benefit-Risk Assessment
  • Safety Evaluation
  • Regulatory Affairs, Pharmacovigilance
  • PV Governance
  • Safety Surveillance
  • Pharmacovigilance Operations
  • PV Inspection and Audit Readiness
  • Patient Support Programs
  • Market Research Programs
  • Clinical Safety
  • Medical Safety
  • Medical Information
  • Pharmacoepidemiology
  • Quality Assurance, Pharmacovigilance